Applying for Rosacea Research Grants
The Rosacea Research Foundation funds grants based on the following criteria.
(1) The research must be novel in origin,
(2) The research must have some applicability to rosacea treatment, and
(3) The research must be geared towards the underlying pathology.
The Rosacea Research Foundation funds both benchwork biomedical research and human clinical trials. We fund several levels of research, including small grants ($10,000 to $15,000), medium-sized grants ($20,000 to $40,000), and large-sized grants ($40,000+).
The Medical Advisory Committee is responsible for reviewing funding requests and making recommendations to The Board. Both bodies ensure that research undertaken fulfills the goals of the Rosacea Research Foundation.
Grant Allocation Announcement
12th October 2005
The Rosacea Research Foundation has allocated 2005 donated funds to an excellent grant.
STRUCTURAL AND BIOLOGIC CHANGES IN ROSACEA SKIN
INDUCED BY PULSE DYE LASER AND INTENSE PULSED LIGHT
Dr. Payam Tristani-Firouzi, Assistant Professor,
Dr. Nancy Samolitis, Visiting Professor,
Department of Dermatology,
University of Utah School of Medicine.
Drs. Tristani and Samolitis plan to examine the effect of pulse dye laser
(PDL) and intense pulsed light (IPL) treatment of rosacea to determine
whether, in addition to reducing the amount of blood vessels, these
procedures produce structural and biologic change in the skin that may
help identify and increase understanding of the causes of this disorder.
The researchers will visually and microscopically assess the primary
features of rosacea before and after treatment with PDL and IPL, including
redness (erythema), visible blood vessels (telangiectasia), bumps
(papules) and pimples (pustules).
In addition, biopsy samples before and after treatment will be tested for
factors that are increasingly recognized as playing a potential role in
the development of rosacea. These will include the presence of
inflammatory cells (perifollicular inflammatory infiltrate), vascular
endothelial growth factor (VEGF), interleukin-1 (IL-1) and factor XIII.
The researchers will also assess the size of oil (sebaceous) glands and
the presence of Demodex mites, a normal inhabitant of human skin that has
been observed in greater numbers in rosacea patients.
The study will include 10 patients with subtype 1
(erythematotelangiectatic) rosacea and subtype 2 (papulopustular) rosacea,
each received treatment on one side of the face with the other side
serving as a control. The overall severity of these signs of rosacea will
also be evaluated by the patients.
NRS Expresses Gratitude to the RRF
We have received a letter of thanks from the NRS. This letter outlines how the NRS hopes that its research funding activities will continue to grow. Please support the NRS now and into the future.
The RRF has paid $11,800 to the NRS, who has passed this money on the successful grant applicants. This is the first half of the required and awarded $23,600. The RRF is unable to provide all of the required remaining funds, so the NRS will cover the difference.
This represents a milestone for the RRF. Well done and thanks to all of our supporters.
As part of winding up our operations, the remainder of the RRF's funds have been sent to the NRS to further fund the approved grant.